Q1 2023 Earnings Conference Call

Thursday, May 4, 2023, at 5:00PM EDT



© 2023 Identiv, Inc. | All Rights Reserved | NASDAQ: INVE

Safe Harbor

Note Regarding Forward-Looking Information

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are those involving future events and future results that are based on current expectations as well as the current beliefs and assumptions of the Company's management and can be identified by words such as "anticipates", "believes", "plans", "will", "intends", "expects", and similar references to the future. Any statement that is not a historical fact, including statements regarding the Company's expectations regarding its future operating and financial outlook and performance, including 2023 guidance and growth expectations; the Company's plans to accelerate growth; the Company's beliefs regarding its ability to deliver on its current 2023 outlook; expected benefits of the Company's Thailand production facility and timing of production runs, the Company's strategy, business outlook, business drivers and opportunities; the Company's expectations regarding backlog, customer orders, production capacity and supply constraints; the Company's beliefs regarding its competitive position, are forward-looking statements. Forward-looking statements are only predictions and are subject to a number of risks and uncertainties, many of which are outside our control, which could cause actual results to differ materially and adversely from those expressed in any forward-looking statements. Factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to the Company's ability to continue the momentum in its business, its ability to satisfy customer demand and expectations, the level and timing of semiconductors and the other risk factors discussed in its periodic reports, including its Annual Report on Form 10-K for the year ended December 31, 2022 filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information available to us on the date hereof, and we a

Non-GAAP Financial Measures (Unaudited)

This presentation includes financial information that has not been prepared in accordance with GAAP, including non-GAAP adjusted EBITDA, non-GAAP adjusted EBITDA margin, non-GAAP gross margin, and non-GAAP operating expenses. Identiv uses non-GAAP financial measures internally in analyzing its financial results and believes they are useful to investors, as a supplement to GAAP measures, in evaluating our ongoing operational performance. We believe that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends. The non-GAAP measures discussed above exclude items that are included in GAAP net income (loss), GAAP operating expenses and GAAP gross margin. For historical periods, the exclusions are detailed in the reconciliation table included in this presentation. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Investors are encouraged to review the reconciliation of the non-GAAP measures to their most directly comparable GAAP financial measures as detailed in this presentation.

Trademarks

This presentation contains trademarks, service marks, trade names and copyrights of Identiv and other companies, and are the property of their respective owners.





I. Q1 2023 Highlights

- II. Financial Review
- III. 2023 Business Drivers




Q1 2023 Business Highlights

- Identity Segment Updates
 - Shipped 43 million units; maintained 100% RFID customer retention; supported 54 NRE projects
 - Delivered 10 million units to Ambient IoT leader Wiliot; on pace to deliver 14 million units in Q2 2023
 - Confirmed follow-on order of similar magnitude with Wiliot for delivery in 2023
 - Auto-injector syringe project design-in sent for FDA approval
 - Chip availability improving; partnered with ProQure to launch new NFC Type 2 tags
 - Thailand production facility on track to begin first production runs in July
 - Bitse.io SaaS platform ease of use and value demonstrated


• Premises Segment Updates

- Federal sales grew 16% year-over-year; strong physical security backlog going into Q2 2023
- Launched complete Velocity Vision Ecosystem: access control, video, and analytics
- Industry's most complete, integrated solution: Velocity Ecosystem + TS Readers & Credentials
- Vertical adoption: Schools, Airports, Municipalities, Federal, Transit, First Responders, Hospitals

Delivered 10 million Wiliot IoT Pixels and Confirmed Follow-On Order



Expanded Velocity Vision Ecosystem





Q1 2023 Financial Overview


Financial Overview

Metric	Q1′23	Q4′22	Q1′22
Revenue	\$26.0M	\$29.0M	\$25.1M
Recurring Revenue (% of Revenue)	6%	5%	6%
GAAP Gross Margin	35.4%	36.5%	35.8%
Non-GAAP Gross Margin	37.1%	37.9%	37.1%
GAAP Operating Expenses	\$11.9M	\$10.2M	\$10.0M
Non-GAAP Operating Expenses	\$10.6M	\$9.3M	\$9.0M
GAAP Net Income (Loss)	(\$2.7M)	\$0.3M	\$(1.0M)
EPS (GAAP) Diluted	(\$0.13)	\$0.00	\$(0.06)
Non-GAAP Adj. EBITDA	(\$0.9M)	\$1.7M	\$0.2M
Non-GAAP Adj. EBITDA Margin	-4%	6%	1%

IDENTIV

Please refer to a reconciliation of Non-GAAP to GAAP later in this presentation, in the Q1 2022 earnings release dated May 4, 2022, or in the Q4 2022 earnings release dated March 2, 2023. May include rounding differences.

Segment Revenue and Non-GAAP Gross Margin




7 © 2023 Identiv, Inc. | All Rights Reserved | NASDAQ: INVE

Please refer to a reconciliation of Non-GAAP to GAAP later in this presentation or in prior earnings releases. May include rounding differences.



Total Revenue and Non-GAAP Adjusted EBITDA Operating Expenses



8 © 2023 Identiv, Inc. | All Rights Reserved | NASDAQ: INVE

Please refer to a reconciliation of Non-GAAP to GAAP later in this presentation or in prior earnings releases. May include rounding differences.

I PENTIV

Q1 2023 Cash Flow and Balance Sheet (in \$M)



Assets	Q1'22	Q4'22	Q1'23	Liabilities & Equity	Q1'22	Q4'22	Q1'23	Cash Flow	Q1'22	Q4'22	Q1'23
Cash & cash											
equivalents*	28.7	17.1	21.2	Accounts payable	11.3	14.8	9.9	From operations*	0.0	(4.8)	(4.7)
Accounts											
receivable	19.5	24.8	21.1	Financial liabilities	0.0	0.0	9.9	From investing	(0.5)	(0.9)	(1.2)
Inventory	20.5	29.0	30.6	Other liabilities	9.7	12.6	12.1	From financing	(0.4)	(0.1)	9.8
Other assets	2.7	4.2	4.4	Total equity	73.8	75.4	73.6	FX effect	(0.2)	1.1	0.2
Total	71.3	75.1	77.3	Total	94.9	102.8	105.6	Total	(1.1)	(4.8)	4.0

I DENTIV

2023 Business Drivers

2023 Overall Strategy





Healthcare and Medical Device Use Cases

End user	Status	Application
	Active	Medical Device
	Active	Medical Device (Cartridge for quick-test)
	Active	Medical Device (Lab Tester)
	Active	Medical Device (Ventilators)
	Active	Drug Test
	Active	Medical Device
	Active	Pharma
	Active	Pharma
	Active	X-ray films
	Active	Medical Device (Tester)
	Active	Blood Bags (cold chain monitoring)
	Active	imaging film
	Active	Medical Device (monitoring)
	Active	Identification of Medical Cartridges
	Active	dispenser
	Active	Reagent label
	Active	Consumables authentication
	Active	Medical Device
	Active, NRE (NDA	
	Signed)	Medical Device (

End user	Status	Application
	Early stage	Blood Bags
	Early Stage	Medical Device (
	Evaluation	Medical Device (
	Evaluation	Drug Test/Bandage
	Evaluation	Pharma/Med Device (Autoinjector)
	Evaluation	Material Tracking
	Evaluation	Material Tracking
	Evaluation	Medical Device (
	Evaluation, NRE	Pharma/Med Device (Autoinjector)
	Evaluation, NRE	Pharma/Med Device (
	NRE	Identification of Medical Cartridges
	NRE	Smart Pharma Packaging
	On Hold	Drug Test
	On Hold	Dental
	Qualification	Medical Device
	Sample testing	Drug
	Sample testing	Smart Bandages
	Testing	Medical Device
	Testing	Identification of Medical Cartridges
	Testing	Healthcare cold chain



2023 IoT Business Drivers



• IoT Strategy

- Expanded product range:
 - Full range of standardized NFC and ruggedized UHF products
 - Wiliot/BLE-enabled IoT
 - bitse.io SaaS platform
- Build technical lead in key verticals: medical & pharma, specialty packaging, industrial
- Expand capacity and cost competitiveness via our Thailand facility
- Growth Drivers
 - Medical & Healthcare: five auto-injector projects; more than half NRE projects in medical vertical
 - Wiliot: supporting both passive and battery-assisted devices; on track to deliver 14 million units in 2H 2023 and confirmed a follow-on order of similar magnitude for delivery in 2023
 - Smart Packaging: maintaining strong position with cannabis and smart packaging partners; will grow as end users grow
 - SaaS platform: IoT device management, consumer experience & data analytics
- IoT Partnerships
 - Collect-ID: customer engagement applications (European football, NHL hockey, auto racing)
 - STMicroelectronics: new form factors and designs based on their ST25TN chips
 - ProQure: high-performance, cost-competitive NFC Type 2 tags
- Expanding Production Capacity in Thailand
 - On track and expected to begin first production runs in July 2023



2023 Premises Business Drivers

• Industry's Most Complete Platform

- Integrated security platform combining Velocity Ecosystem across access control, video, and analytics with TouchSecure readers and credentials
- Complete sales & services teams in place with go-tomarket strategy
- Increasing commercial verticals and expanding across Federal agencies & internationally
- OEM strategy: expanding technology platform; efficient channel to market
- Planning new product launches include EG2 edge gateway, Primis SMB access system and multi-factor authentication reader later this year





THANK YOU

Q&A Session

Visit identiv.com for more information today.



Income Statement (unaudited, in \$'000)

Identiv, Inc. Condensed Consolidated Statements of Operations (in thousands, except per share data) (unaudited)

	Three Months Ended						
	Μ	larch 31,	Dec	ember 31,	March 31,		
		2023		2022		2022	
Net revenue	\$	25,997	\$	29,001	\$	25,061	
Cost of revenue		16,786		18,421		16,095	
Gross profit		9,211		10,580		8,966	
Operating expenses:							
Research and development		2,707		2,283		2,529	
Selling and marketing		6,097		5,021		5,110	
General and administrative		2,948		2,806		2,488	
Restructuring and severance		191		70		(140)	
Total operating expenses		11,943		10,180		9,987	
Income (loss) from operations		(2,732)		400		(1,021)	
Non-operating income (expense):							
Interest expense, net		(50)		(42)		(25)	
Gain on investment						24	
Foreign currency gains (losses), net		89		44		19	
Income (loss) before income tax benefit (provision)		(2,693)		402		(1,003)	
Income tax benefit (provision)		(26)		(63)		4	
Net income (loss)		(2,719)		339		(999)	
Cumulative dividends on Series B convertible preferred stock		(313)		(304)		(298)	
Net income (loss) available to common stockholders	\$	(3,032)	\$	35	\$	(1,297)	
Net income (loss) per common share:							
Basic	\$	(0.13)	\$	0.00	\$	(0.06)	
Diluted	\$	(0.13)	\$	0.00	\$	(0.06)	
Weighted average shares used in computing net income (loss) per common share:							
Basic		22,794		22,737		22,574	
Diluted		22,794		23,160		22,574	



Balance Sheet (in \$'000)

Identiv, Inc. Condensed Consolidated Balance Sheets (in thousands) (unaudited)

]	March 31, 2023	December 31, 2022		
ASSETS					
Current assets:					
Cash and cash equivalents	\$	20,804	\$	16,650	
Restricted cash		363		487	
Accounts receivable, net of allowances		21,136		24,826	
Inventories		30,609		28,958	
Prepaid expenses and other current assets		4,361		4,177	
Total current assets		77,273		75,098	
Property and equipment, net		7,595		6,719	
Operating lease right-of-use assets		4,344		4,373	
Intangible assets, net		4,999	5,26		
Goodwill		10,192	10,19		
Other assets		1,148		1,120	
Total assets	\$	105,551	\$	102,765	
LIABILITIES AND STOCKHOLDERS' EQUI Current liabilities:	TY				
Accounts payable	\$	9,926	\$	14,760	
Financial liabilities		9,941		—	
Operating lease liabilities		1,199		1,190	
Deferred revenue		1,798		2,068	
Accrued compensation and related benefits		2,395		2,757	
Other accrued expenses and liabilities		2,648		2,618	
Total current liabilities		27,907	_	23,393	
Long-term operating lease liabilities		3,371		3,366	
Long-term deferred revenue		647		587	
Other long-term liabilities		25		25	
Total liabilities		31,950		27,371	
Total stockholders' equity		73,601		75,394	
Total liabilities and stockholders' equity	\$	105,551	\$	102,765	



Non-GAAP Reconciliation

	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	FY 2022	Q1 2023
Reconciliation of GAAP gross margin and non-GAAP gross margin											
GAAP gross margin (%)	35%	37%	38%	33%	36%	36%	37%	36%	36%	36%	35%
GAAP gross profit	\$7.7	\$8.8	\$11.1	\$9.4	\$37.1	\$9.0	\$10.2	\$11.2	\$10.6	\$ 41.0	\$9.2
Stock-based compensation	\$0.0	\$0.0	\$0.0	\$0.0	\$0.2	\$0.1	\$0.0	\$0.0	\$0.1	\$0.2	\$0.0
Amortization and depreciation	\$0.2	\$0.3	\$0.3	\$0.3	\$1.0	\$0.3	\$0.3	\$0.3	\$0.3	\$1.3	\$0.4
Total reconciling items included in GAAP gross profit	\$0.3	\$0.3	\$0.3	\$0.3	\$1.2	\$0.3	\$0.4	\$0.4	\$0.4	\$1.5	\$0.4
Non-GAAP gross profit	\$8.0	\$9.1	\$11.4	\$9.7	\$38.3	\$9.3	\$10.6	\$11.6	\$11.0	\$42.4	\$9.6
Non-GAAP gross margin (%)	36%	38%	39%	34%	37%	37%	38%	37%	38%	38%	37%
Reconciliation of GAAP operating expenses to non-GAAP operating expenses											
GAAP operating expenses	\$8.9	\$9.1	\$9.1	\$11.3	\$38.4	\$10.0	\$10.5	\$10.6	\$10.2	\$41.3	\$11.9
Stock-based compensation	(\$0.7)	(\$0.6)	(\$0.5)	(\$0.5)	(\$2.4)	(\$0.8)	(\$0.8)	(\$0.8)		(\$3.0)	(\$0.9)
Amortization and depreciation	(\$0.2)	(\$0.2)	(\$0.2)	(\$0.2)	(\$1.0)	(\$0.2)	(\$0.2)	(\$0.3)	(\$0.2)	(\$1.0)	(\$0.2)
Loss on disposal of property and equipment	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	(\$0.1)	(\$0.1)	\$0.0
Change in fair value of earnout liability	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Acquisition related transaction costs	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Restructuring and severance	(\$0.4)	(\$0.3)	(\$0.1)	(\$0.1)	(\$0.8)		(\$0.2)	(\$0.0)	(\$0.1)	(\$0.2)	(\$0.2)
Total reconciling items included in GAAP operating expenses	(\$1.4)	(\$1.2)	(\$0.9)	(\$0.8)	(\$4.2)	(\$0.9)	(\$1.2)	(\$1.1)	(\$0.9)	(\$4.2)	(\$1.4)
Non-GAAP operating expenses	\$7.6	\$8.0	\$8.2	\$10.5	\$34.2	\$9.0	\$9.2	\$9.5	\$9.3	\$37.1	\$10.6
Reconciliation of GAAP net income (loss) to non-GAAP adjusted EBITDA										_	
GAAP net income (loss)	(\$1.5)	\$2.5	\$2.5	(\$1.9)	\$1.6	(\$1.0)	(\$0.3)	\$0.5	\$0.3	(\$0.4)	(\$2.7)
Income tax provision (benefit)	\$0.0	\$0.0	\$0.0	(\$0.1)	\$0.0	(\$0.0)	\$0.1	(\$0.0)	\$0.1	\$0.1	\$0.0
Interest expense, net	\$0.2	\$0.1	\$0.1	\$0.0	\$0.5	\$0.0	\$0.0	\$0.0	\$0.0	\$0.1	\$0.1
Gain on forgiveness of Paycheck Protection Program note	\$0.0	(\$2.9)	\$0.0	\$0.0	(\$2.9)	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Gain on sale of investment	\$0.0	\$0.0	(\$0.6)	\$0.0	(\$0.6)	(\$0.0)	(\$0.0)	\$0.0	\$0.0	(\$0.0)	\$0.0
Foreign currency (gains) losses, net Stock-based compensation	\$0.0 \$0.8	\$0.0 \$0.7	\$0.0 \$0.6	\$0.1 \$0.6	\$0.1 \$2.6	(\$0.0) \$0.9	(\$0.1) \$0.8	\$0.0 \$0.9	(\$0.0) \$0.6	(\$0.2) \$3.2	(\$0.1) \$1.0
Amortization and depreciation	\$0.8 \$0.5	\$0.7 \$0.5	\$0.5	\$0.8 \$0.5	\$2.0 \$1.9	\$0.9 \$0.5	\$0.8 \$0.6	\$0.9 \$0.6	\$0.6	\$3.2 \$2.3	\$1.0 \$0.6
Loss on disposal of property and equipment	ψ0.5	+	\$0.0	+	•		+			\$2.3 \$0.1	\$0.0 \$0.0
	\$0.0	\$0.0					\$0.0	\$0.0	\$0.1		
	\$0.0 \$0.0	\$0.0 \$0.0		\$0.0 \$0.0	\$0.0 \$0.0	\$0.0 \$0.0	\$0.0 \$0.0	\$0.0 \$0.0	\$0.1 \$0.0		+
Change in fair value of earnout liability Acquisition related transaction costs	\$0.0 \$0.0 \$0.0	\$0.0 \$0.0 \$0.0	\$0.0 \$0.0 \$0.0	\$0.0 \$0.0 \$0.0	\$0.0 \$0.0 \$0.0	\$0.0 \$0.0 \$0.0	\$0.0 \$0.0 \$0.0	\$0.0 \$0.0 \$0.0	\$0.1 \$0.0 \$0.0	\$0.0 \$0.0 \$0.0	\$0.0 \$0.0
Change in fair value of earnout liability Acquisition related transaction costs	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0 \$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Change in fair value of earnout liability	\$0.0 \$0.0	\$0.0 \$0.0	\$0.0 \$0.0	\$0.0 \$0.0	\$0.0 \$0.0	\$0.0	\$0.0 \$0.0	\$0.0 \$0.0	\$0.0 \$0.0	\$0.0 \$0.0	\$0.0 \$0.0
Change in fair value of earnout liability Acquisition related transaction costs Restructuring and severance	\$0.0 \$0.0 \$0.4	\$0.0 \$0.0 \$0.3	\$0.0 \$0.0 \$0.1	\$0.0 \$0.0 \$0.1	\$0.0 \$0.0 \$0.8	\$0.0 \$0.0 (\$0.1)	\$0.0 \$0.0 \$0.2	\$0.0 \$0.0 \$0.0	\$0.0 \$0.0 \$0.1	\$0.0 \$0.0 \$0.2	\$0.0 \$0.0 \$0.2

IDENTIV